Neoadjuvant Systemic Therapy and the Surgical Management of Breast Cancer

Surgical Clinics of North America

Volumn 87, Issue 2, 2007, Pages 399-415

  Waljee, Jennifer F ^a   Newman, Lisa A ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; THIOTEPA; VINCRISTINE; VINDESINE;

ADD ON THERAPY; ADVANCED CANCER; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; DISEASE FREE SURVIVAL; DRUG INDICATION; DRUG TARGETING; EARLY CANCER; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MORBIDITY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34247846154     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.02.004     Document Type: Review

References (74)

1. Kaufmann M., Hortobagyi G.N., Goldhirsch A., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24 12 (2006) 1940-1949
2. Cristofanilli M., Gonzalez-Angulo A., Sneige N., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23 1 (2005) 41-48
3. Newman L.A., Buzdar A.U., Singletary S.E., et al. A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility. Ann Surg Oncol 9 3 (2002) 228-234
4. Bear H.D., Anderson S., Brown A., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21 22 (2003) 4165-4174
5. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
6. Smith I.C., Heys S.D., Hutcheon A.W., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20 6 (2002) 1456-1466
7. Hamilton A., and Hortobagyi G. Chemotherapy: what progress in the last 5 years?. J Clin Oncol 23 8 (2005) 1760-1775
8. Dixon J.M., Jackson J., Renshaw L., et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 86 3-5 (2003) 295-299
9. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a Phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
10. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
11. von Minckwitz G., Costa S.D., Raab G., et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open Phase IIb study. J Clin Oncol 19 15 (2001) 3506-3515
12. Abrial C., Mouret-Reynier M.A., Cure H., et al. Neoadjuvant endocrine therapy in breast cancer. Breast 15 1 (2006) 9-19
13. American College of Surgeons Oncology Group Protocol Z1031. Available at: www.acosog.org. Accessed April 1, 2007.
14. Wolmark N., Wang J., Mamounas E., et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
15. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 7 (1997) 2483-2493
16. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005) 188-194
17. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 (1999) 460-469
18. von Minckwitz G., Raab G., Caputo A., et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23 12 (2005) 2676-2685
19. von Minckwitz G., Blohmer J.U., Raab G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 16 1 (2005) 56-63
20. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46 5 (1986) 2578-2581
21. Scholl S.M., Fourquet A., Asselain B., et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 30 5 (1994) 645-652
22. Mauriac L., MacGrogan G., Avril A., et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10 1 (1999) 47-52
23. Mauriac L., Durand M., Avril A., et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol 2 5 (1991) 347-354
24. Scholl S.M., Asselain B., Palangie T., et al. Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer 27 12 (1991) 1668-1671
25. Scholl S.M., Pierga J.Y., Asselain B., et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31 12 (1995) 1969-1975
26. Powles T.J., Hickish T.F., Makris A., et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13 3 (1995) 547-552
27. Makris A., Powles T.J., Ashley S.E., et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9 11 (1998) 1179-1184
28. Makris A., Powles T.J., Dowsett M., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3 4 (1997) 593-600
29. Semiglazov V.F., Topuzov E.E., Bavli J.L., et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in Stage IIb-IIIa breast cancer. Ann Oncol 5 7 (1994) 591-595
30. Gazet J.C., Ford H.T., Gray R., et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann Oncol 12 5 (2001) 685-691
31. Danforth Jr. D.N., Cowan K., Altemus R., et al. Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy for Stage II breast cancer: a prospective randomized trial. Ann Surg Oncol 10 6 (2003) 635-644
32. van der Hage J.A., van de Velde C.J., Julien J.P., et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 22 (2001) 4224-4237
33. Singletary S.E., McNeese M.D., and Hortobagyi G.N. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer 69 11 (1992) 2849-2852
34. Chagpar A.B., Middleton L.P., Sahin A.A., et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243 2 (2006) 257-264
35. Touboul E., Lefranc J.P., Blondon J., et al. Primary chemotherapy and preoperative irradiation for patients with Stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol 42 3 (1997) 219-229
36. Rouzier R., Extra J.M., Carton M., et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol 19 18 (2001) 3828-3835
37. Calais G., Berger C., Descamps P., et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer 74 4 (1994) 1283-1288
38. Chen A.M., Meric-Bernstam F., Hunt K.K., et al. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol 22 12 (2004) 2303-2312
39. Kuerer H.M., and Newman L.A. Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 23 8 (2005) 1698-1705
40. Krag D.N., Weaver D.L., Alex J.C., et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 2 6 (1993) 335-339 [discussion: 40]
41. Schwartz G.F. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J 10 2 (2004) 85-88
42. Senn H.J., Thurlimann B., Goldhirsch A., et al. Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer. Breast 12 6 (2003) 569-582
43. Krishnamurthy S., Sneige N., Bedi D.G., et al. Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 95 5 (2002) 982-988
44. Sabel M.S., Schott A.F., Kleer C.G., et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 186 2 (2003) 102-105
45. Schrenk P., Hochreiner G., Fridrik M., et al. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J 9 4 (2003) 282-287
46. Ollila D.W., Neuman H.B., Sartor C., et al. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg 190 (2005) 371-375
47. Khan A., Sabel M.S., Nees A., et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol 12 9 (2005) 697-704
48. Neuman H., Carey L.A., Ollila D.W., et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg 191 6 (2006) 827-829
49. Breslin T.M., Cohen L., Sahin A., et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 18 20 (2000) 3480-3486
50. Nason K.S., Anderson B.O., Byrd D.R., et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89 11 (2000) 2187-2194
51. Schwartz G.F., and Meltzer A.J. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J 9 5 (2003) 374-379
52. Fernandez A., Cortes M., Benito E., et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 22 4 (2001) 361-366
53. Julian T.B., Dusi D., and Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 184 4 (2002) 315-317
54. Haid A., Tausch C., Lang A., et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma?. Cancer 92 5 (2001) 1080-1084
55. Reitsamer R., Peintinger F., Rettenbacher L., et al. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol 84 2 (2003) 63-67
56. Aihara T., Munakata S., Morino H., et al. Feasibility of sentinel node biopsy for breast cancer after neoadjuvant endocrine therapy: a pilot study. J Surg Oncol 85 2 (2004) 77-81
57. Kinoshita T., Takasugi M., Iwamoto E., et al. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg 191 2 (2006) 225-229
58. Miller A.R., Thomason V.E., Yeh I.T., et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 9 3 (2002) 243-247
59. Tafra L., Verbanac K.M., and Lannin D.R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 182 4 (2001) 312-315
60. Balch G.C., Mithani S.K., Richards K.R., et al. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for Stage II and III breast cancer. Ann Surg Oncol 10 6 (2003) 616-621
61. Brady E.W. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 8 2 (2002) 97-100
62. Piato J.R., Barros A.C., Pincerato K.M., et al. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy. A pilot study. Eur J Surg Oncol 29 2 (2003) 118-120
63. Shimazu K., Tamaki Y., Taguchi T., et al. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer 100 12 (2004) 2555-2561
64. Jones J.L., Zabicki K., Christian R.L., et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 190 4 (2005) 517-520
65. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 12 (2005) 2694-2702
66. Newman EA, Sabel M, Nees A, et al. Sentinel lymph node biopsy following neoadjuvant chemotherapy is Accurate in patients with documented nodal metastases at presentation. Ann Surg Onc, in press.
67. Stearns V., Ewing C.A., Slack R., et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 9 3 (2002) 235-242
68. Singletary S.E. Neoadjuvant chemotherapy in the treatment of Stage II and III breast cancer. Am J Surg 182 4 (2001) 341-346
69. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 8 (1998) 2672-2685
70. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 1 (1999) 72-78
71. Hennessy B.T., Hortobagyi G.N., Rouzier R., et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 23 36 (2005) 9304-9311
72. Pierga J.Y., Mouret E., Dieras V., et al. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer 83 11 (2000) 1480-1487
73. Kuerer H.M., Newman L.A., Smith T.L., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17 2 (1999) 460-469
74. Lenert J.T., Vlastos G., Mirza N.Q., et al. Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. Ann Surg Oncol 6 8 (1999) 762-767